Condition
High Risk
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownTracking Risk in Adolescents and Children for Early Identification of Common Mental DisordersNCT07744490 · 2026-07-25
NOT_YET_RECRUITINGAdjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)NCT05778097 · 2023-04-01
NOT_YET_RECRUITINGTauropace to Prevent Cardiac Implantable Device Infections in Heart Failure PatientsNCT05103267 · 2022-06-06
UNKNOWNImaging vs. no Testing in Asymptomatic High-risk Diabetic PatientsNCT04388280 · 2021-01-28
UNKNOWN68 Ga-PSMA for High Risk Prostate CancerNCT04614363 · 2020-10-13
COMPLETEDTeplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"NCT01030861 · 2010-08-01
COMPLETEDPhase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)NCT00590785 · 1996-08-13
COMPLETEDCommon interventions
Leading sponsors
Clinical Centre of Serbia1Federico II University1National Cancer Institute (NCI)1National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1Shanghai Mental Health Center1The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1The Methodist Hospital Research Institute1
Trial status mix
COMPLETED3
NOT_YET_RECRUITING2
UNKNOWN2
Phase mix
PHASE23
NA1
PHASE11
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.